CardioTech's hydrogel wound dressing gains FDA OK:
This article was originally published in Clinica
CardioTech International has gained US FDA 510(k) clearance for its absorbent hydrogel wound and burn dressing, which it claims has a reduced tendency to adhere to skin lesions. The dressing, which does not need to be removed from the wound for inspection, is indicated for treating skin ulcers, pressure sores, abrasions, lacerations, incisions and burns, including those associated with resurfacing procedures, such as dermabrasion, chemical and laser resurfacing. The product is aimed at a potential $300m market, says the Woburn, Massachusetts firm.
You may also be interested in...
Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.
Among the largest gaps in safety data is non-clinical research on CBD use's effect on developing fetus and adolescent brain, in utero/lactational exposure, reproductive toxicity and the potential for a latency period before toxicity, says FDA neuroscientist Andrew Shen.
The templates from the US agency provide guidance to manufacturers developing antibody tests for clinical or at-home use.